内容へ

中間型・軽症型βサラセミア

胎児ヘモグロビン合成の薬理学的誘導

ヒドロキシ尿素(ヒドロキシカルバミド)療法

Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (新しいタブで開く)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

出典‎: Hemoglobin 2014;38(1):44-8.

インデックス‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (新しいタブで開く)

Hydroxyurea in thalassemia intermedia--a promising therapy. (新しいタブで開く)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

出典‎: Ann Hematol 2005;84(7):441-6.

インデックス‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (新しいタブで開く)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (新しいタブで開く)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

出典‎: J Clin Pathol 2010;63(2):147-50.

インデックス‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (新しいタブで開く)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (新しいタブで開く)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

出典‎: Eur J Haematol 2010;84(1):52-8.

インデックス‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (新しいタブで開く)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (新しいタブで開く)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

出典‎: Blood Cells Mol Dis 2000;26(5):453-66.

インデックス‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (新しいタブで開く)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (新しいタブで開く)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

出典‎: Ann N Y Acad Sci 2005;1054:250-6.

インデックス‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (新しいタブで開く)

遺伝子組み換えエリスロポエチン(単独または他の製剤と併用)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (新しいタブで開く)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

出典‎: Acta Haematol 2004;111(4):189-95.

インデックス‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (新しいタブで開く)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (新しいタブで開く)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

出典‎: Blood Purif 2004;22(5):453-60.

インデックス‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (新しいタブで開く)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (新しいタブで開く)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

出典‎: Br J Haematol 2011;154(2):281-4.

インデックス‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (新しいタブで開く)